Sarepta Therapeutics (SRPT) Inventory Average (2016 - 2026)

Sarepta Therapeutics' Inventory Average history runs 11 years deep, the most recent figure standing at $957.9 million for Q1 2026.

• In Q1 2026, Inventory Average rose 13.27% year-over-year to $957.9 million; the TTM figure through Mar 2026 stood at $957.9 million (up 13.27% YoY), while the FY2025 annual figure was $832.4 million, up 55.17% from the prior year.
• Inventory Average for Q1 2026 stood at $957.9 million, down from $996.0 million in the prior quarter.
• The five-year high for Inventory Average was $1.0 billion in Q3 2025, with the low at $192.6 million in Q1 2022.
• The 5-year median for Inventory Average is $348.2 million (2024), against an average of $501.5 million.
• The sharpest annual moves came in 2022 and 2025: Inventory Average retreated 22.96% in 2022, then jumped 142.88% in 2025.
• Sarepta Therapeutics' Inventory Average stood at $212.6 million in 2022, then soared by 33.33% to $283.4 million in 2023, then surged by 132.13% to $657.9 million in 2024, then surged by 51.37% to $996.0 million in 2025, then retreated by 3.82% to $957.9 million in 2026.
• Business Quant data shows SRPT's Inventory Average at $957.9 million in Q1 2026, $996.0 million in Q4 2025, and $1.0 billion in Q3 2025.